Literature DB >> 3040158

Oestrogen receptor activity in intraduct and invasive breast carcinomas.

R A Hawkins, A L Tesdale, W A Ferguson, J J Going.   

Abstract

Breast cancers analysed for oestrogen receptor activity over a ten-year period have been surveyed in order to select a group of intraduct carcinomas without invasion and a second, control group of invasive carcinomas without intraduct carcinoma. Examination of histological sections taken from the face of the tumour samples used for receptor analysis showed only 13 purely intraduct carcinomas without any invasion. Each of these was matched for age, menstrual status, hospital of origin, and approximate assay date with two purely invasive ductal carcinomas of no specialized type (26 invasive carcinomas in all). In invasive carcinomas, a significantly higher proportion of the specimen was occupied by malignant cells (mean 30%) than in the intraduct carcinomas (mean 15%), and receptors were detected more frequently (77% versus 46%) and at higher concentrations (mean 26 times on a wet weight basis, 19 times on a protein basis). When allowance was made for the difference in cellularity between the groups, the invasive carcinomas still contained significantly higher concentrations of receptor protein (mean = ten times more on a wet weight basis). These findings suggest that the expression of the gene encoding the receptor protein tends to be a property either maintained, or acquired upon progression to invasive disease. Further studies will be needed to determine whether or not the established prognostic and predictive values of receptor measurements apply to non-invasive disease, and to clarify the relationship between receptor expression in benign and malignant breast in relation to morphological changes.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3040158     DOI: 10.1007/BF01807365

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  19 in total

1.  Oncogenes homologous to steroid receptors?

Authors:  M Sluyser; J Mester
Journal:  Nature       Date:  1985 Jun 13-19       Impact factor: 49.962

2.  Steroid receptors: oncogenes as hormone receptors.

Authors:  J M Bishop
Journal:  Nature       Date:  1986 May 8-14       Impact factor: 49.962

3.  Adjuvant tamoxifen therapy and receptor levels.

Authors:  H J Stewart; R Prescott
Journal:  Lancet       Date:  1985-03-09       Impact factor: 79.321

4.  The prevention of breast cancer.

Authors:  J Cuzick; D Y Wang; R D Bulbrook
Journal:  Lancet       Date:  1986-01-11       Impact factor: 79.321

5.  Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.

Authors:  K S McCarty; L S Miller; E B Cox; J Konrath; K S McCarty
Journal:  Arch Pathol Lab Med       Date:  1985-08       Impact factor: 5.534

6.  Hormones as cancer growth factors.

Authors:  L Israel; P Band
Journal:  Lancet       Date:  1984-10-13       Impact factor: 79.321

7.  Correlation of primary breast cancer histopathology and estrogen receptor content.

Authors:  E R Fisher; C K Osborne; W L McGuire; C Redmond; W A Knight; B Fisher; G Bannayan; A Walder; E J Gregory; A Jacobsen; D M Queen; D E Bennett; H C Ford
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

8.  Oestrogen receptor concentration in primary breast cancer and axillary node metastases.

Authors:  R A Hawkins; R Black; R J Steele; J M Dixon; A P Forrest
Journal:  Breast Cancer Res Treat       Date:  1981       Impact factor: 4.872

9.  Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast tumors.

Authors:  W J King; E R DeSombre; E V Jensen; G L Greene
Journal:  Cancer Res       Date:  1985-01       Impact factor: 12.701

10.  Factors that promote the development of human breast cancer.

Authors:  D B Thomas
Journal:  Environ Health Perspect       Date:  1983-04       Impact factor: 9.031

View more
  6 in total

1.  Distribution of estrogen and progesterone receptors in healthy tissue adjacent to breast lesions at various stages--immunohistochemical study of 107 cases.

Authors:  J D Jacquemier; J Hassoun; M Torrente; P M Martin
Journal:  Breast Cancer Res Treat       Date:  1990-02       Impact factor: 4.872

2.  Oestrogen receptor activity in breast cancer detected at a prevalence screening examination.

Authors:  M M Roberts; R A Hawkins; F E Alexander; T J Anderson; R J Steele
Journal:  Breast Cancer Res Treat       Date:  1987-12       Impact factor: 4.872

Review 3.  William L. McGuire Memorial Symposium. Estrogen and progestin effects in human breast carcinogenesis.

Authors:  R J King
Journal:  Breast Cancer Res Treat       Date:  1993       Impact factor: 4.872

4.  Prevalence of aneuploidy, overexpressed ER, and overexpressed EGFR in random breast aspirates of women at high and low risk for breast cancer.

Authors:  C J Fabian; C Zalles; S Kamel; B F Kimler; R McKittrick; A S Tranin; S Zeiger; W P Moore; R S Hassanein; C Simon
Journal:  Breast Cancer Res Treat       Date:  1994       Impact factor: 4.872

5.  Immunohistochemical study of D5 antigen (an oestrogen receptor related protein) in normal breast, benign breast disease, and mammary carcinoma in situ.

Authors:  A Girling; M Caleffi; R J King; R R Millis
Journal:  J Clin Pathol       Date:  1988-04       Impact factor: 3.411

6.  Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy.

Authors:  S G Archer; A Eliopoulos; D Spandidos; D Barnes; I O Ellis; R W Blamey; R I Nicholson; J F Robertson
Journal:  Br J Cancer       Date:  1995-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.